Alvesco
ciclesonide
Treatment for AsthmaAventis Receives Approvable Letter from U.S. Food and Drug Administration for Alvesco (ciclesonide) for Treatment of Persistent Asthma
BAD HOMBURG, Germany, and PARIS, France, October 26, 2004 – ALTANA AG (NYSE: AAA, FSE: ALT) and Aventis (NYSE:AVE), part of the sanofi-aventis Group, announced today the receipt of an approvable letter from the U.S. Food and Drug Administration (FDA) for Alvesco (ciclesonide) for the treatment of persistent asthma (regardless of severity) in adults, adolescents and children four years of age and older. ALTANA and Aventis signed an agreement in 2001 to jointly develop and market Alvesco in the United States.
An approvable letter outlines specific issues that must be resolved before the Agency will approve a product for marketing. Aventis is already working closely with the FDA to address the clinical data requests outlined in the letter.
About sanofi-aventis
The sanofi-aventis Group is the world’s 3rd largest
pharmaceutical company, ranking number 1 in Europe. Backed by a
world-class R&D organization, sanofi-aventis is developing
leading positions in seven major therapeutic areas: cardiovascular
disease, thrombosis, oncology, diabetes, central nervous system,
internal medicine, vaccines. The sanofi-aventis Group is listed in
Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
About ALTANA
ALTANA AG is an international pharmaceuticals and chemicals group
with sales of about EUR2.6 billion and more than 10,500 employees
worldwide. Its pharmaceuticals group, ALTANA Pharma, concentrates
on areas such as therapeutics and self-medication, and focuses on
innovative pharmaceutical research in the areas of
gastrointestinal, respiratory, and oncology. Located in Constance,
Germany, ALTANA Pharma represents a group of 28 subsidiaries and
associated companies in Europe, the Americas and Asia.
Related Articles:
Alvesco Gains FDA Approval for the U.S. Market - January 16, 2008
Aventis Submits New Drug Application to FDA for Asthma Drug Alvesco (ciclesonide) - January 1, 2004
New Drug Applications Archive
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
